Kostiantyn Turcheniuka,
Tetiana Dumychb,
Rostyslav Bilyybc,
Volodymyr Turcheniukad,
Julie Bouckaertb,
Volodymyr Vovkc,
Valentyna Chopyakc,
Vladimir Zaitsevde,
Pascal Mariotf,
Natasha Prevarskayaf,
Rabah Boukherrouba and
Sabine Szunerits*a
aInstitut d'Electronique, de Microélectronique et de Nanotechnologie (IEMN), UMR CNRS8520, Université Lille 1, Avenue Poincaré-BP 60069, 59652 Villeneuve d'Ascq, France. E-mail: sabine.szunerits@univ-lille1.fr
bUnité de Glycobiologie Structurale et Fonctionnelle (UGSF), Université Lille 1, CNRS UMR 8576, 59655 Villeneuve d'Ascq, France
cDanylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine
dTaras Shevchenko University, 60 Vladimirskaya str., Kiev, Ukraine
eChemistry Department, Pontifical Catholic University of Rio de Janeiro, Rua Marques de Sao Vicente, 225-Gavea, Rio de Janeiro, 22451-900, Brazil
fLaboratoire de Physiologie Cellulaire INSERM U1003, Equipe Labellisée par la Ligue Nationale, Contre le Cancer et LABEX (Laboratoire d'excellence), Université Lille 1, 59655 Villeneuve d'Ascq, France
First published on 6th December 2024
Expression of concern for ‘Plasmonic photothermal cancer therapy with gold nanorods/reduced graphene oxide core/shell nanocomposites’ by Kostiantyn Turcheniuk et al., RSC Adv., 2016, 6, 1600–1610, https://doi.org/10.1039/C5RA24662H.
Laura Fisher
5th November 2024
Executive Editor, RSC Advances
This journal is © The Royal Society of Chemistry 2024 |